- Home
- RSSS vs MGNX Comparison
RSSS vs MGNX Comparison
Compare RSSS & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RSSS
- MGNX
- Stock Information
- Founded
- RSSS 2006
- MGNX 2000
- Country
- RSSS United States
- MGNX United States
- Employees
- RSSS N/A
- MGNX N/A
- Industry
- RSSS Business Services
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- RSSS Consumer Discretionary
- MGNX Health Care
- Exchange
- RSSS Nasdaq
- MGNX Nasdaq
- Market Cap
- RSSS 90.6M
- MGNX 87.7M
- IPO Year
- RSSS N/A
- MGNX 2013
- Fundamental
- Price
- RSSS $2.95
- MGNX $1.61
- Analyst Decision
- RSSS
- MGNX Hold
- Analyst Count
- RSSS 0
- MGNX 9
- Target Price
- RSSS N/A
- MGNX $5.33
- AVG Volume (30 Days)
- RSSS 44.9K
- MGNX 1.3M
- Earning Date
- RSSS 05-08-2025
- MGNX 08-05-2025
- Dividend Yield
- RSSS N/A
- MGNX N/A
- EPS Growth
- RSSS N/A
- MGNX N/A
- EPS
- RSSS N/A
- MGNX N/A
- Revenue
- RSSS $48,753,578.00
- MGNX $154,050,000.00
- Revenue This Year
- RSSS $12.42
- MGNX N/A
- Revenue Next Year
- RSSS $7.47
- MGNX N/A
- P/E Ratio
- RSSS N/A
- MGNX N/A
- Revenue Growth
- RSSS 14.85
- MGNX 255.31
- 52 Week Low
- RSSS $2.32
- MGNX $0.99
- 52 Week High
- RSSS $4.24
- MGNX $5.77
- Technical
- Relative Strength Index (RSI)
- RSSS 54.66
- MGNX 59.02
- Support Level
- RSSS $2.94
- MGNX $1.34
- Resistance Level
- RSSS $3.10
- MGNX $1.65
- Average True Range (ATR)
- RSSS 0.09
- MGNX 0.11
- MACD
- RSSS 0.02
- MGNX 0.04
- Stochastic Oscillator
- RSSS 62.45
- MGNX 91.40
About RSSS Research Solutions Inc
Research Solutions Inc is a holding company. The company provides a cloud-based SaaS research intelligence platform consisting of proprietary software and Internet-based interfaces. Its platform also allows customers to find and download digital versions of STM articles. Platforms and Transactions are packaged as a single solution that enables life science and other research-intensive organizations to speed up research and development activities. The company platform allows customers to initiate orders, manage transactions, automate authentication, obtain reports, and connect seamlessly to corporate intranets.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.